Plain-English translation of NCT07204639 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Psoriasis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing CBP-0276, an oral medication that participants would take twice daily for 36 weeks (about 9 months). Researchers want to see whether this medication can safely reduce psoriasis severity, clear skin plaques, and improve how psoriasis affects daily life. Half of participants will receive the medication while the other half receive a placebo (inactive pill), and no one—including the research team—will know which group you're in until the trial ends.
Psoriasis is a chronic skin disease that significantly impacts quality of life, and while several treatments exist, there is an ongoing need for safe and effective oral medications. This trial is exploring whether this new treatment could offer another option for people with moderate to severe psoriasis who need systemic (body-wide) therapy.
You likely qualify if…
You likely don't qualify if…
You would visit the research site multiple times over 36 weeks to receive your assigned treatment (either the medication or placebo) and have your psoriasis assessed using standard skin evaluations and questionnaires about how psoriasis affects your daily life. Blood tests may be done to check safety and measure inflammation levels. Throughout the trial, the research team would monitor you for any side effects or changes in your psoriasis severity.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
Mexico